U.S. jury hits Takeda, Eli Lilly with $9 billion penalty
TOKYO — A U.S. jury ordered Takeda Pharmaceutical Co. and Eli Lilly to pay $9 billion in punitive damages over a diabetes medicine linked to cancer, but Japan's biggest drugmaker said Tuesday it will “vigorously challenge” the decision.
The U.S District Court in western Louisiana decided a $6 billion penalty for Takeda and $3 billion for its business partner and co-defendant Eli Lilly. It also ordered $1.5 million in compensatory damages in favor of the plaintiff.
The legal fight turned on whether Actos, which is a drug used to treat type-two diabetes, caused a patient's bladder cancer and by implication was responsible for other cases of the cancer.
Takeda and Eli Lilly are facing numerous other lawsuits over the drug, which allege failure to warn about side effects and concealment of its health risks.
Kenneth Greisman, a general counsel at Takeda, said in a statement that the evidence does not support a link between Actos and bladder cancer.
“Takeda respectfully disagrees with the verdict, and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal,” he said.
Punitive damages are often reduced on appeal.
In June 2011, the U.S. Food and Drug Administration published a drug safety update on Actos, which said there was a 40 percent increase in bladder cancer risk in people who used the drug for longer than a year. It required that the cancer risk be added to the medication's warning label. Actos has been sold since 1999.
Actos comes with warnings about various serious side effects, including liver problems and higher risk of broken bones.
A former Takeda medical reviewer, Helen Ge, alleged in a U.S. District Court filing in 2012 that the Japanese drugmaker understated the number of bladder cancer cases possibly linked to Actos in its disclosures to the FDA.
Shares of Osaka-based Takeda tanked on the Tokyo Stock Exchange, closing down 5.2 percent.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Consumer spending dips 0.1% in July as auto sales pull back
- Deported migrants find home at call centers
- Students walk shop class path to excellence
- Lower your cable bill by streaming shows
- Compelling cases exist for cashing out, staying in as stock market soars
- U-PARC houses companies ranging from innovative to traditional
- States clear way for startups to use crowdfunding
- States fight back against financial scams aimed at seniors
- PPG research helps vehicle, plane makers cut pounds from products
- Healthy PA expands number of recipients but cuts benefits
- Dairy Queen victim of malware attack